In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Where this comes from
- Record sourced from PubMed, PMID 33939480.
- Also identified by DOI 10.7326/ACPJ202105180-053.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wheeler DC, Stefánsson BV, Jongs N, et al. <b>Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.</b> Lancet Diabetes Endocrinol. 2021;9:22-31. 33338413.
Medical subject headings
- Diabetes Mellitus, Type 2
- Renal Insufficiency, Chronic